Related Experiment Videos
GnRH agonists.
1Department of Obstetrics and Gynecology, University of Tennessee, Memphis 38163.
Clinical Obstetrics and Gynecology
|September 1, 1989
Summary
Gonadotropin-releasing hormone (GnRH) agonists offer effective ovarian suppression for gynecological conditions. Short-term use is beneficial for fibroids and endometriosis, while long-term use requires careful risk-benefit analysis due to potential side effects.
Area of Science:
- Gynecology
- Reproductive Endocrinology
Background:
- Gonadotropin-releasing hormone (GnRH) agonists have significantly impacted gynecological and reproductive endocrinology practices.
- Their clinical utility is poised to expand with improved administration and defined indications.
Purpose of the Study:
- To review the current and potential applications of GnRH agonists in gynecology.
- To differentiate between short-term and long-term uses and their associated benefits and risks.
Main Methods:
- Review of current literature on GnRH agonist applications.
- Categorization of indications into short-term (<6 months) and long-term (>6 months) suppression.
Main Results:
- Short-term GnRH agonist therapy is effective for preoperative fibroid treatment, ovulation induction, endometriosis suppression, and diagnostic purposes.
- Long-term therapy shows success in precocious puberty and metastatic cancers, but carries risks like hot flashes and osteoporosis, necessitating careful risk-benefit assessment for other indications.
Conclusions:
- GnRH agonists provide a reversible method for ovarian suppression.
- Optimizing long-term GnRH agonist therapy may involve dose reduction or combination with hormone replacement to mitigate side effects.